Modern principles of etiotropic therapy for chronic hepatitis B and C

Abstract

The review includes an analysis of literature data on the etiotropic therapy of chronic viral hepatitis B and C. In this review, we focused on the efficacy and safety of drugs that have been included in international and Russian guidelines for etiotropic therapy of chronic viral hepatitis B and C. The analysis of the feasibility of using antiviral drugs in real clinical practice was carried out, based on research data on the study of the mechanisms of action, efficacy and possible side effects of these drugs.

Keywords

antiviral therapy / chronic hepatitis B / chronic hepatitis C / nucleotide analogues / pegylated interferon / direct antiviral drugs / efficacy

References

[1] Global hepatitis report. 2017 [Internet]. WHO. Available from: http://apps.who.int/iris/bitstream/10665/255017/1/WHO-HIV-2017.06-eng.pdf. Accessed: 23.11.2022.

[2] Global hepatitis report 2017 [Электронный ресурс] // World Health Organization. Режим доступа: http://apps.who.int/iris/bitstream/10665/255017/1/WHO-HIV-2017.06-eng.pdf. Дата обращения: 23.11.2022.

[3] The Lancet. Towards elimination of viral hepatitis by 2030. Lancet. 2016;388(10042):308. DOI: 10.1016/S0140-6736(16)31144-8

[4] The Lancet. Towards elimination of viral hepatitis by 2030 // Lancet. 2016. Vol. 388, No. 10042. P. 308. DOI: 10.1016/S0140-6736(16)31144-8

[5] Howell J, Pedrana A, Cowie BC, et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol. 2019;34(1):40–48. DOI: 10.1111/jgh.14457

[6] Howell J., Pedrana A., Cowie B.C. et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030 // J. Gastroenterol. Hepatol. 2019. Vol. 34, No. 1. P. 40–48. DOI: 10.1111/jgh.14457

[7] European Association for the Study of the Liver, et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–1218. DOI: 10.1016/j.jhep.2020.08.018

[8] European Association for the Study of the Liver. et al. EASL recommendations on treatment of hepatitis C: Final update of the series // J. Hepatol. 2020. Vol. 73, No. 5. P. 1170–1218. DOI: 10.1016/j.jhep.2020.08.018

[9] Maticic M, Mondelli MU. Elimination of viral hepatitis: where do we stand in the year 2020? Clin Microbiol Infect. 2020;26(7):816–817. DOI: 10.1016/j.cmi.2020.02.029.

[10] Maticic M., Mondelli M.U. Elimination of viral hepatitis: where do we stand in the year 2020? // Clin. Microbiol. Infect. 2020. Vol. 26, No. 7. P. 816–817. DOI: 10.1016/j.cmi.2020.02.029.

[11] Gosudarstvennyy doklad. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2021 godu [Internet]. Available from: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=21796&ysclid=lc6koh6knz755728296. Accessed: 23.11.2022. (In Russ.)

[12] Государственный доклад. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2021 году [Электронный ресурс]. Режим доступа: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=21796&ysclid=lc6koh6knz755728296. Дата обращения: 23.11.2022.

[13] Mikhaylov MI, Yushchuk ND, Malinnikova EYu, et al. The design of the program for control and elimination of viral hepatitis as public health problem in the Russian federation. Infectious Diseases: News, Opinions, Training. 2018;7(2(25)):52–58. (In Russ.). DOI: 10.24411/2305-3496-2018-12005

[14] Михайлов М.И., Ющук Н.Д., Малинникова Е.Ю. и др. Проект программы по контролю и ликвидации вирусных гепатитов как проблема общественного здоровья в Российской Федерации // Инфекционные болезни: Новости. Мнения. Обучение. 2018. Т. 7, № 2(25). С. 52–58. DOI: 10.24411/2305-3496-2018-12005

[15] Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology. 2019;156:297–310. DOI: 10.1053/j.gastro.2018.10.048

[16] Ward J.W., Hinman A.R. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats // Gastroenterology. 2019. Vol. 156. P. 297–310. DOI: 10.1053/j.gastro.2018.10.048

[17] European Association for the Study of the Liver, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. DOI: 10.1016/j.jhep.2017.03.021

[18] European Association for the Study of the Liver. et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection // J. Hepatol. 2017. Vol. 67, No. 2. P. 370–398. DOI: 10.1016/j.jhep.2017.03.021

[19] Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63(1):284–306. DOI: 10.1002/hep.28280

[20] Lok A.S., McMahon B.J., Brown R.S. Jr. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis // Hepatology. 2016. Vol. 63, No. 1. P. 284–306. DOI: 10.1002/hep.28280

[21] Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015;313(16):1617–1618. DOI: 10.1001/jama.2015.2571

[22] Perrillo R.P., Martin P., Lok A.S. Preventing hepatitis B reactivation due to immunosuppressive drug treatments // JAMA. 2015. Vol. 313, No. 16. P. 1617–1618. DOI: 10.1001/jama.2015.2571

[23] Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422–430. DOI: 10.1002/hep.23327

[24] Chang T.T., Lai C.L., Kew Yoon S. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B // Hepatology. 2010. Vol. 51, No. 2. P. 422–430. DOI: 10.1002/hep.23327

[25] Chang T-T, Liaw Y-F, Wu S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893. DOI: 10.1002/hep.23785

[26] Chang T.-T., Liaw Y.-F., Wu S.-S. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B // Hepatology. 2010. Vol. 52. P. 886–893. DOI: 10.1002/hep.23785

[27] Liaw YF. Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy. J Hepatol. 2013;59:880–881. DOI: 10.1016/j.jhep.2013.05.007

[28] Liaw Y.F. Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy // J. Hepatol. 2013. Vol. 59. P. 880–881. DOI: 10.1016/j.jhep.2013.05.007

[29] Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, Phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195. DOI: 10.1016/S2468-1253(16)30024-3

[30] Chan H.L., Fung S., Seto W.K. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, Phase 3, non-inferiority trial // Lancet Gastroenterol. Hepatol. 2016. Vol. 1, No. 3. P. 185–195. DOI: 10.1016/S2468-1253(16)30024-3

[31] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, Phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206. DOI: 10.1016/S2468-1253(16)30107-8

[32] Buti M., Gane E., Seto W.K. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, Phase 3, non-inferiority trial // Lancet Gastroenterol. Hepatol. 2016. Vol. 1. P. 196–206. DOI: 10.1016/S2468-1253(16)30107-8

[33] Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58(3):872–880. DOI: 10.1002/hep.26436

[34] Sonneveld M.J., Hansen B.E., Piratvisuth T. et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels // Hepatology. 2013. Vol. 58, No. 3. P. 872–880. DOI: 10.1002/hep.26436

[35] Sonneveld MJ, Brouwer WP, van der Meer AJ. Posttreatment hepatitis B surface antigen seroreversion: The bane of combination therapy in chronic hepatitis B? Gastroenterology. 2016;150(5):1254–1255. DOI: 10.1053/j.gastro.2015.12.047

[36] Sonneveld M.J., Brouwer W.P., van der Meer A.J. Posttreatment hepatitis B surface antigen seroreversion: The bane of combination therapy in chronic hepatitis B? // Gastroenterology. 2016. Vol. 150, No. 5. P. 1254–1255. DOI: 10.1053/j.gastro.2015.12.047

[37] Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection — EASL Special Conference. J Hepatol. 2015;63(5):1238–1253. DOI: 10.1016/j.jhep.2015.06.026

[38] Lampertico P., Maini M., Papatheodoridis G. Optimal management of hepatitis B virus infection — EASL Special Conference // J. Hepatol. 2015. Vol. 63, No. 5. P. 1238–1253. DOI: 10.1016/j.jhep.2015.06.026

[39] Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013;7(1):88–97. DOI: 10.1007/s12072-012-9343-x

[40] Marcellin P., Bonino F., Yurdaydin C. et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients // Hepatol. Int. 2013. Vol. 7, No. 1. P. 88–97. DOI: 10.1007/s12072-012-9343-x

[41] Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2):434. DOI: 10.3390/v14020434

[42] Chien R.N., Liaw Y.F. Current trend in antiviral therapy for chronic hepatitis B // Viruses. 2022. Vol. 14, No. 2. P. 434. DOI: 10.3390/v14020434

[43] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. DOI: 10.1002/hep.28156

[44] Terrault N.A., Bzowej N.H., Chang K.M. et al. AASLD guidelines for treatment of chronic hepatitis B // Hepatology. 2016. Vol. 63, No. 1. P. 261–283. DOI: 10.1002/hep.28156

[45] Zeng H, Li L, Hou Z, et al. Direct-acting antiviral in the treatment of chronic hepatitis C: Bonuses and challenges. Int J Med Sci. 2020;17(7):892–902. DOI: 10.7150/ijms.43079

[46] Zeng H., Li L., Hou Z. et al. Direct-acting antiviral in the treatment of chronic hepatitis C: Bonuses and challenges // Int. J. Med. Sci. 2020. Vol. 17, No. 7. P. 892–902. DOI: 10.7150/ijms.43079

[47] Klinicheskiye rekomendatsii “Khronicheskiy virusnyy gepatit C (KHVGS) u vzroslykh” [Internet]. Available from: http://www.consultant.ru/document/cons_doc_LAW_327011/. Accessed: 23.11.2022. (In Russ.)

[48] Клинические рекомендации «Хронический вирусный гепатит C (ХВГС) у взрослых» [Электронный ресурс]. Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_327011/. Дата обращения: 23.11.2022.

[49] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. DOI: 10.1016/j.jhep.2016.09.001

[50] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016 // J. Hepatol. 2017. Vol. 66, No. 1. P. 153–194. DOI: 10.1016/j.jhep.2016.09.001

[51] Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The first pangenotypic direct-acting antiviral combination for hepatitis C. Ann Pharmacother. 2017;51(1):44–53. DOI: 10.1177/1060028016668897

[52] Chahine E.B., Sucher A.J., Hemstreet B.A. Sofosbuvir/Velpatasvir: The first pangenotypic direct-acting antiviral combination for hepatitis C // Ann. Pharmacother. 2017. Vol. 51, No. 1. P. 44–53. DOI: 10.1177/1060028016668897

[53] Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int. 2020;40(8):1841–1852. DOI: 10.1111/liv.14537

[54] Mangia A., Milligan S., Khalili M. et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts // Liver Int. 2020. Vol. 40, No. 8. P. 1841–1852. DOI: 10.1111/liv.14537

[55] Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71:660–665. DOI: 10.1016/j.jhep.2019.05.028

[56] Borgia S.M., Dearden J., Yoshida E.M. et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis // J. Hepatol. 2019. Vol. 71. P. 660–665. DOI: 10.1016/j.jhep.2019.05.028

[57] Nelson DR, Cooper JN, Lalezari JP, et al. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135. DOI: 10.1002/hep.27726

[58] Nelson D.R., Cooper J.N., Lalezari J.P. et al. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study // Hepatology. 2015. Vol. 61, No. 4. P. 1127–1135. DOI: 10.1002/hep.27726

[59] Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378:354–369. DOI: 10.1056/NEJMoa1702417

[60] Zeuzem S., Foster G.R., Wang S. et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection // N. Engl. J. Med. 2018. Vol. 378. P. 354–369. DOI: 10.1056/NEJMoa1702417

[61] Atsukawa M, Tsubota A, Toyoda H, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019;49(9):1230–1241. DOI: 10.1111/apt.15218

[62] Atsukawa M., Tsubota A., Toyoda H. et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study // Aliment. Pharmacol. Ther. 2019. Vol. 49, No. 9. P. 1230–1241. DOI: 10.1111/apt.15218

[63] Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018;68(4):1298–1307. DOI: 10.1002/hep.30046

[64] Reau N., Kwo P.Y., Rhee S. et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection // Hepatology. 2018. Vol. 68, No. 4. P. 1298–1307. DOI: 10.1002/hep.30046

[65] Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases — Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. DOI: 10.1002/hep.31060

[66] Ghany M.G., Morgan T.R.; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases — Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection // Hepatology. 2020. Vol. 71, No. 2. P. 686–721. DOI: 10.1002/hep.31060

[67] Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64(2):301–307. DOI: 10.1016/j.jhep.2015.10.005

[68] Feld J.J., Moreno C., Trinh R. et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks // J. Hepatol. 2016. Vol. 64, No. 2. P. 301–307. DOI: 10.1016/j.jhep.2015.10.005

[69] Abergel A, Asselah T, Mallat A, et al. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int. 2020;40(8):1853–1859. DOI: 10.1111/liv.14502

[70] Abergel A., Asselah T., Mallat A. et al. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis // Liver Int. 2020. Vol. 40, No. 8. P. 1853–1859. DOI: 10.1111/liv.14502

[71] Wei L, Jia JD, Wang FS, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019;34(1):12–21. DOI: 10.1111/jgh.14509

[72] Wei L., Jia J.D., Wang F.S. et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study // J. Gastroenterol. Hepatol. 2019. Vol. 34, No. 1. P. 12–21. DOI: 10.1111/jgh.14509

[73] Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371–378. DOI: 10.1002/hep.28995

[74] Balistreri W.F., Murray K.F., Rosenthal P. et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection // Hepatology. 2017. Vol. 66, No. 2. P. 371–378. DOI: 10.1002/hep.28995

[75] El-Araby HA, Behairy BE, El-Guindi MA, et al. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents. Hepatol Int. 2019;13(6):706–714. DOI: 10.1007/s12072-019-09985-w

[76] El-Araby H.A., Behairy B.E., El-Guindi M.A. et al. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents // Hepatol. Int. 2019. Vol. 13, No. 6. P. 706–714. DOI: 10.1007/s12072-019-09985-w

[77] Burnevich EZ, Gusev DA, Znoyko OO, et al. Efficacy and safety of narlaprevir/ritonavirand daclatasvir combination in the treatment naive, noncirrhotic patients with hepatitis c virus genotype 1b. Klinicheskaya farmakologiya i terapiya. 2018;27(4):35–39. (In Russ.)

[78] Бурневич Э.З., Гусев Д.А., Знойко О.О. и др. Эффективность и безопасность нарлапревира/ритонавира в комбинации с даклатасвиром у ранее не получавших противовирусную терапию больных хроническим гепатитом С без цирроза печени, инфицированных вирусом гепатита С генотипа 1b // Клиническая фармакология и терапия. 2018. Т. 27, № 4. С. 35–39.

[79] Klimova EA, Burnevich EZ, Chulanov VP, et al. Efficacy and safety of narlaprevir/ritonavir and daclatasvir non i.nterferon combination in population of Russian patients with chronic hepatitis C. Ter Arkhiv. 2019;91(8):67–74. (In Russ.). DOI: 10.26442/00403660.2019.08.000384

[80] Климова Е.А., Бурневич Э.З., Чуланов В.П. и др. Эффективность и безопасность безинтерфероновой комбинации нарлапревир/ритонавир и даклатасвир в популяции российских пациентов с хроническим гепатитом С // Терапевтический архив. 2019. Т. 91, № 8. С. 67–74. DOI: 10.26442/00403660.2019. 08.000384

[81] Grushko IP, Romanova EB, Tverdokhlebova TI, et al. Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C. Ter Arkh. 2022;94(8):979–984. (In Russ.). DOI: 10.26442/00403660.2022.08.201774

[82] Грушко И.П., Романова Е.Б., Твердохлебова Т.И. и др. Сравнительная оценка эффективности нарлапревира в составе интерфероновой и безинтерфероновой схем лечения больных хроническим гепатитом С // Терапевтический архив. 2022. Т. 94, № 8. С. 979–984. DOI: 10.26442/00403660.2022.08.201774

[83] Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122–1126. DOI: 10.1002/hep.23444

[84] Martinot-Peignoux M., Stern C., Maylin S. et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin // Hepatology. 2010. Vol. 51, No. 4. P. 1122–1126. DOI: 10.1002/hep.23444

RIGHTS & PERMISSIONS

Eco-Vector